<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The occurrence of treatment-related <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> after adjuvant therapy with <z:chebi fb="0" ids="22333">alkylating agents</z:chebi> for <z:e sem="disease" ids="C0685938" disease_type="Neoplastic Process" abbrv="">gastrointestinal cancers</z:e>, <z:mp ids='MP_0003579'>ovarian carcinoma</z:mp>, and <z:hpo ids='HP_0003002'>breast cancer</z:hpo> and after treatment for <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e>, non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, <z:mpath ids='MPATH_310'>germ-cell tumors</z:mpath>, and <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> has been well documented </plain></SENT>
<SENT sid="1" pm="."><plain>Adjuvant chemotherapy is frequently used for the treatment of early stage <z:hpo ids='HP_0003002'>breast cancer</z:hpo>, and to date there has been no increase in the incidence of secondary <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> or <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> after <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>-based regimens when compared with surgical controls </plain></SENT>
<SENT sid="2" pm="."><plain>This report describes two patients who developed <z:hpo ids='HP_0004808'>acute myelocytic leukemia</z:hpo> only after exposure to <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="44185">methotrexate</z:chebi>, and <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> adjuvant therapy </plain></SENT>
<SENT sid="3" pm="."><plain>These two cases of <z:hpo ids='HP_0002488'>acute leukemia</z:hpo>, which developed 3 years after diagnosis of <z:hpo ids='HP_0003002'>breast cancer</z:hpo> and initiation of chemotherapy, were characterized by trilineage <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and <z:hpo ids='HP_0001876'>pancytopenia</z:hpo>, and had abnormalities of chromosomes 5 and 7: characteristics consistent with treatment-related <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Many women are diagnosed with early stage <z:hpo ids='HP_0003002'>breast cancer</z:hpo> each year who are potential candidates for adjuvant therapy </plain></SENT>
<SENT sid="5" pm="."><plain>Although certain subgroups of patients have been shown to benefit from adjuvant therapy, continued efforts must be directed at identifying responders so that others will not be exposed to the additional risks of chemotherapy </plain></SENT>
</text></document>